Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart

Circulation

Volumn 94, Issue 11, 1996, Pages 2817-2825

  Gilbert, Edward M ^a   Abraham, William T ^b   Olsen, Stephanie ^a   Hattler, Brack ^b   White, Michel ^b   Mealy, Patrice ^a   Larrabee, Patti ^a   Bristow, Michael R ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

heart failure; nervous system, autonomic; receptors, adrenergic, beta

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; METOPROLOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; FEMALE; HEART CATHETERIZATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART STROKE VOLUME; HEMODYNAMICS; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0029845423     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.11.2817     Document Type: Article

References (44)

1. Yoshikawa, T, Port JD, Asano K, Chidiak, P, Bouvier M, Dutcher D, Roden RL, Minobe W, Tremmel KD, Bristow MR. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J. 1996;17(suppl B):8-16.
2. Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol. 1993;71:12C-22C.
3. Ruffolo RR, Gallai M, Hieble JP, Willette RN, Nichols AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol. 1990;38:S82-S88.
4. Bristow MR, Larrabee P, Muller-Beckmann B, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin Invest. 1992;70:S105-S113.
5. Bristow MR, Larrabee P, Minobe W. Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol. 1992;19(suppl 1):S68-S80.
6. DiLenarda A, Gilbert EM, Olsen SL, Mealey PC, Bristow MR. Acute hemodynamic effects of carvedilol versus metoprolol in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1991;17:142A. Abstract.
7. Metra M, Nardi M, Giubbini R, DeiCas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994;24:1678-1687.
8. Yue T-L, Cheng H-Y, Lysko PG, McKenna PJ, Feuerstein R, Gu J-L, Lysko KA, Davis LL, Feuerstein G. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 1992;263:92-98.
9. Ohlstein EH, Douglas SA, Sung CP, Yue T-L, Louden C, Arleth A, Poste G, Ruffolo RR, Feuerstein GZ. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci U S A. 1993;90:6189-6193.
10. Bristow MR, Gilbert EM. Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure. Eur Heart J. 1995;16(suppl F):20-31.
11. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441-1446.
12. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995;25:1225-1231.
13. Pollock SG, Lystash J, Tedesco C, Craddock G, Smucker ML. Usefulness of bucindolol in congestive heart failure. Am J Cardiol. 1990;66:603-607.
14. Eichhorn DJ, Bedotto JB, Malloy CR. Effect of β-adrenergic blockade on myocardial function and energetics in congestive heart failure. Circulation. 1990;82:473-483.
15. Bristow MR, O'Connell JB, Gilbert EM. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation. 1994;89:1632-1642.
16. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HR, Neuberg GW, DeLong G, Packer M. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995;92:1499-1506.
17. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM. Effect of carvedilol on the survival of patients with chronic heart failure. Circulation. 1995;92(suppl I):I-142. Abstract.
18. Packer M, Colucci WS, Sackner-Bernstein J, Liang C-S, Goldschef DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M. Prospective randomized evaluation of carvedilol on symptoms and exercise tolerance in chronic heart failure: results of the PRECISE trial. Circulation. 1995;92(suppl I):I-143. Abstract.
19. Colucci WS, Packer M, Bristow MR, Cohn JN, Fowler MB, Gilbert EM, Krueger SK, Adams KF, Hershberger R, Uretsky BF. Carvedilol inhibits clinical progression in patients with mild heart failure. Circulation. 1995;92(suppl I):I-395. Abstract.
20. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger R, Kubo SH, Narahara KA, Ingersoll H. Multicenter oral carvedilol heart failure assessment (MOCHA): a six-month dose-response evaluation in class II-IV patients. Circulation. 1995;92(suppl I):I-142. Abstract.
21. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: the cardiac insufficiency bisoprolol study. Circulation. 1994;90:1765-1773.
22. White M, Roden RA, Minobe W. Age-related changes in β-adrenergic neuroeffector systems in the human heart. Circulation. 1994;90:1225-1238.
23. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. Assessment of the β-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation. 1986;74:1290-1302.
24. Gilbert EM, Sandoval A, Larrabee P, Renlund DG, O'Connell JB, Bristow MR, Lisinopril lowers cardiac adrenergic drive and increases β-receptor density in the failing human heart. Circulation. 1993;88:472-480.
25. 2-adrenoreceptors. Eur J Pharmacol. 1986;130:137-139.
26. 1 receptor down-regulation in heart failure. Circ Res. 1986;59:297-309.
27. 2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy. J Cardiovasc Pharmacol. 1986;8:1235-1242.
28. Heilbrunn SM, Shaf P, Bristow MR. Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989;79:483-490.
29. Waagstein F, Caidahl K, Wallentin I, Bergh C-H, Hjalmarson A. Long-term β-blockade in dilated cardiomyopathy: effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation. 1989;80:551-563.
30. Anderson JL, Gilbert EM, O'Connell JB, Renlund D, Yanowitz F, Murray M, Roskelley M, Mealey P, Volkman K, Deitchman D, Bristow M. Long-term (2 year) beneficial effects of beta-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1991;17:1373-1381.
31. Hall SA, Cigarroa CG, Marxoux L, Risser RC, Graybum PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol. 1995;25:1154-1161.
32. Chidiac P, Hebert TE, Valiquette M, Dennis M, Bouvier M. Inverse agonist activity of β-adrenergic antagonists. Mol Pharmacol. 1994;45:490-499.
33. 2-adrenergic receptor. Science. 1994;264:582-586.
34. White M, Yanowitz F, Gilbert EM, Larrabee P, O'Connell JB, Anderson J, Renlund D, Mealey P, Abraham WT, Bristow MR. Role of β-adrenergic receptor downregulation in the peak exercise response of subjects with heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol. 1995;76:1271-1276.
35. Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol. 1993;22(suppl A):61A-71A.
36. Hjemdahl P, Olsson G. Rebound phenomena following withdrawal of long-term β-adrenoceptor blockade. Acta Med Scand. 1982;665:43-47.
37. 2-adrenoceptors in human atrial myocardium. Circ Res. 1990;66:1610-1623.
38. Olsson G, Daleskog M, Hjemdahl P, Rehnqvist N. Unchanged peripheral sympathetic activity following withdrawal of chronic metoprolol treatment: a study of noradrenaline concentrations and kinetics in plasma. Br J Clin Pharmacol. 1984;18:573-579.
39. 1-blockade in human congestive heart failure: acute effects on cardiac sympathetic activity. Circulation. 1995;92(suppl I):I-395. Abstract.
40. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, Malloy CR. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1994;24:1310-1320.
41. Heesch CM, Marcoux L, Hatfield B, Eichhorn EJ. Hemodynamic and energetic comparison of bucindolol and metoprolol for the treatment of congestive heart failure. Am J Cardiol. 1995;75:360-364.
42. Andersson B, Blomstrom-Lundqvist C, Hedner T, Waagstein F. Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure. J Am Coll Cardiol. 1991;18:1059-1066.
43. Murray DP, Watson RDS, Zezulka AV, Murray RG, Littler WA. Plasma catecholamine levels in acute myocardial infarction: influence of beta-adrenergic blockade and relation to central hemodynamics. Am Heart J. 1988;115:38-44.
44. Hattori Y, Nakaya H, Endou M, Nakao Y, Kanno M. Vascular effects of carvedilol, a new β-adrenoceptor antagonist with vasodilating properties, in isolated canine coronary artery. J Cardiovasc Pharmacol. 1989;13:572-579.